Skip to main content
. Author manuscript; available in PMC: 2014 Feb 28.
Published in final edited form as: Int J Pharm. 2013 Jan 28;444(0):185–192. doi: 10.1016/j.ijpharm.2013.01.001

Fig. 4. MWReg30 plasma pharmacokinetics.

Fig. 4

125I-MWReg30was injected intravenously at 0.04, 0.1, and 0.4 mg/kg into C57BL/6 wild type (WT), FcγRI/RIII(−/−), and FcγRIIb(−/−) mice. MWReg30 mean plasma concentrations (nM) following doses of 0.04, 0.1, and 0.4 mg/kg are represented by symbols. Error bars indicate the standard deviation associated with each mean concentration (n=3–5/dose/strain). The plot depicts the dose-normalized MWReg30 concentration (nM/mg/kg) vs. time profiles at 0.04, 0.1, and 0.4 mg/kg in all mouse strains at all doses. The symbols represent mean dose normalized MWReg30 concentrations. Error bars represent the standard deviation associated with mean concentration/dose. Relative to results found in control mice, MWReg30 pharmacokinetics were not altered in FcγRI/RIII(−/−) mice or in FcγRIIb(−/−) mice.